TIDMSCLP
RNS Number : 1039T
Scancell Holdings Plc
10 October 2017
10 October 2017
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell appoints Dr Cliff Holloway as Chief Executive
Officer
Experienced life sciences executive with in-depth oncology
expertise
Scancell Holdings plc, ('Scancell' or the 'Company') the
developer of novel immunotherapies for the treatment of cancer, is
pleased to announce the appointment of Dr Cliff Holloway as Chief
Executive Officer of Scancell, starting 10 January 2018. Cliff will
seek to drive progress of Scancell's immunotherapy platforms
ImmunoBody(R) and Moditope(R) and oversee their commercialisation.
Cliff succeeds Richard Goodfellow who will remain on the Company's
Board of Directors.
Cliff has over twenty five years' experience in the life
sciences industry. He has held executive management and
directorship positions within the biopharmaceutical and diagnostics
industry over this period, providing expertise in the development
and commercialisation of emerging technologies and drug products,
including licensing, M&A, corporate financing, and operations
management.
Cliff joins Scancell from Benitec Biopharma Ltd, where he held
the role of Chief Business and Operating Officer. Prior to this, he
was Chief Executive Officer and Managing Director of Sienna Cancer
Diagnostics Ltd. He also held the position of Chief Executive
Officer at Immune System Therapeutics Ltd. and Biosceptre
International Ltd. Cliff has a strong pre-existing relationship
with Scancell having been the VP of Business Development at Arana
Therapeutics Limited when Scancell sold their portfolio of
monoclonal antibodies to Arana in 2006. Arana was subsequently
acquired by US-based Cephalon Inc. (now Teva) in 2009.
Cliff holds a Bachelor's degree in Pharmacy and a Ph.D. in
Medicinal Chemistry from the University of Nottingham.
John Chiplin, Executive Chairman of Scancell, commented:
"If it wasn't for the significant achievements of Dr Richard
Goodfellow, Scancell would not be in the position it's in today. We
are about to embark on a Phase 2 checkpoint inhibitor combination
study with our ImmunoBody(R) vaccine, SCIB1, in melanoma; and our
lead Moditope(R), Modi-1, is progressing rapidly towards the
clinic. I would like to thank Richard wholeheartedly for his hard
work and substantial contribution to the business, and look forward
to continue working alongside him on the Board of Directors.
I would also like to welcome Dr Cliff Holloway to Scancell.
Cliff's extensive experience and accomplishments speak volumes and
his expertise in cancer therapeutics will be invaluable as we drive
our immunotherapy vaccines through the clinic, with the aim to
provide new treatment options for patients with debilitating
cancers."
Richard Goodfellow, current Chief Executive Officer of Scancell,
added:
"The appointment of Cliff as CEO will ensure that Scancell has a
leader with the right mix of skills to guide the Company into its
next phase of growth. Cliff is an experienced deal maker which
combined with his deep understanding of the science makes him an
ideal choice for the job. I have known Cliff for over 10 years and
very much look forward to supporting him in his new position."
Commenting on his appointment, Dr Cliff Holloway said:
"Having cemented a business relationship with Scancell in 2006 I
have since followed the Company's significant progress with great
interest. I am delighted to be joining the Scancell team at this
exciting time in the Company's evolution and look forward to
building on the many achievements to date, and to progressing these
important new cancer therapies for patients."
Prof. Lindy Durrant, Chief Scientific Officer, added:
"I am deeply indebted to Richard for his hard work, support and
boundless enthusiasm over the last 17 years which has allowed us to
build the Company into the business it is today. Richard's
experience and involvement will continue to benefit Scancell in
years to come and we are delighted that he will remain working with
the Board."
Dr Clifford Michael Holloway (age 57) is, or has been in the
previous five years, a director or partner of the following
companies:
Current directorships Past directorships
Newstar Ventures Pty Limited Biosceptre International Limited
Immune System Therapeutics Limited
Sienna Cancer Diagnostics Limited
Dr Cliff Holloway was appointed as a CEO of Immune System
Therapeutics Limited on 4 October 2012. On 3 October 2014, the
company was placed into administration and dissolved on 14 January
2015. The deficiency as regards to creditors was approximately
AUD$2.75 million on the total admitted claims of AUD$2.98
million.
Dr Cliff Holloway does not have an interest in any ordinary
shares of Scancell.
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
For Further Information:
Dr John Chiplin, Executive +1 858 900 2646
Chairman Scancell Holdings +44 (0) 20 3727
Dr Richard Goodfellow, CEO Plc 1000
Freddy Crossley (Corporate
Finance) Panmure Gordon & +44 (0) 20 7886
Tom Salvesen (Corporate Broking) Co 2500
+44 (0) 20 3727
Mo Noonan/Simon Conway FTI Consulting 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours without toxicity. The Directors believe that the
Moditope(R) platform could play a major role in the development of
safe and effective cancer immunotherapies in the future.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUKUSRBUARRAA
(END) Dow Jones Newswires
October 10, 2017 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024